MidWest Drug Development Conference
Downtown Capitol District, Omaha, Neb. | Oct. 4-5, 2021
2021-10-04 08:00:00
Register!
Downloads
  • Map & Other Info (Coming soon!)
  • Brochure (Coming soon!)
  • Flyer (Coming soon!)
  • 2021 Program (Coming soon!)
  • 2019 Program
  • 2018 Program
  • Home
  • Schedule
  • Venue
  • Technologies
    • Technologies
    • Institutions
    • Startups
    • Previous Technologies
  • Sponsors
  • News
  • Contact
  • Home
  • Schedule
  • Venue
  • Technologies
    • Technologies
    • Institutions
    • Startups
    • Previous Technologies
  • Sponsors
  • News
  • Contact

Treat glioblastoma with multi-functional natural killer cells and small molecule autophagy inhibitor

Purdue University

Researchers at Purdue University have developed an immunotherapy approach combining cell therapy and a small molecule inhibitor to treat glioblastoma. This devastating cancer is characterized by the heterogeneity of tumor antigens expressed on the surface of the tumor cells. This heterogeneity makes glioblastoma difficult to treat using mono-immunotherapeutic approaches, a treatment option that typically results in resistance to the therapy. Therefore there is a critical need to develop approaches to treat glioblastoma to overcome the heterogeneity of the disease.

The technology developed consists of genetically-engineered natural killer (NK) cells and a small molecule inhibitor. The NK cells target two glioblastoma antigens while also blocking adenosine mediated immunosuppression to increase immune cell infiltration in the tumor microenvironment. Along with the cell therapy small molecule based autophagy inhibition promotes intra-tumoral NK cell infiltration, further increasing the effectiveness of the therapy. The genetic construct has been successfully expressed in NK cells as seen by flow cytometry analysis. NK cells engineered with the construct display significant increases in the killing of a patient-derived glioblastoma cell line when compared to wild-type NK cells. This technology provides the first combination immunotherapy approach toward glioblastoma treatment providing the potential to drastically increase patient survival.

Advantages:

  • Multi-faceted glioblastoma treatment option
  • Increases immune cell infiltration

Potential applications:

  • Glioblastoma therapy
  • Combination therapy

Logo

MIDWEST DRUG DEVELOPMENT CONFERENCE
Bringing together industry and the best university drug development researchers in the Midwest
Downtown Capitol District, Omaha, NE
Oct. 4-5, 2021

Latest News
  • Registrations are now open for 2021 March 25, 2021
  • Planners set initial slate of participants, more to come February 22, 2021
  • MidWest Drug Development Conference plans to return in 2021 January 11, 2021
  • MidWest Drug Development Conference for 2020 is postponed July 15, 2020
Twitter Hightlights
  • 👀 https://t.co/WWaZ16hOhr https://t.co/XErdmyAequ
    5 days ago
  • RT @SharpIdeaHub: Drive change in the world with your research - Attend ABC of #SBIR/#STTR #Funding on April 21 at 8:30 am CST Register: ht…
    6 days ago